Glox Therapeutics awarded grant towards antibiotics against antimicrobial-resistant pathogens
Glox Therapeutics, involved in the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has secured £1 million in grant funding from PACE (Pathways to Antimicrobial Clinical Efficacy).
21 Nov 2024Glox Therapeutics is developing an entirely new class of antimicrobials based on proprietary protein bacteriocin engineering platforms. These potent therapeutics target specific pathogens, or a closely related group of pathogens, to selectively eradicate drug-resistant bacteria with unprecedented efficacy. Unlike conventional antibiotics, these do not harm the human microbiome, ensuring a more effective treatment strategy with reduced side-effects.
PACE (Pathways to Antimicrobial Clinical Efficacy) has awarded Glox Therapeutics £1 million to further the development of its narrow-spectrum antibiotics targeted at E. coli and K. pneumoniae. These frequently multidrug-resistant pathogens are a major cause of serious conditions, such as pneumonia, blood stream infections and recurrent urinary tract infections, and are associated with high levels of antimicrobial resistance (AMR)-related mortality. The initial focus will be on hospital- and ventilator-associated pneumonias.
Dr James Clark, CEO and Co-founder, Glox Therapeutics, said, “We are grateful to PACE for their support and recognising the groundbreaking potential of our unique technology. AMR poses a significant threat to human health globally and this grant will enable us to expand our team and progress the development of our innovative engineered bacteriocins to help combat two of the most life-threatening pathogens.”
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>